Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00028067 · ClinicalTrials.gov registry record · Phase 3

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

A Phase 3 study, sponsored by Bristol-Myers Squibb.

Terminated
Registry status
Phase 3
Development phase
500
Enrollment target

NCT00028067: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.

NCT00028067 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 500 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00028067, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.

TERMINATED
Registry status
Phase 3
Development phase
500 participants
Enrollment target

Study Summary

The purpose of this study is to compare the atazanavir and nelfinavir (NFV) treatments in their ability to reduce viral load.

Interventions

  • DRUG Atazanavir
  • DRUG Nelfinavir mesylate

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2001-08
Est. Completion 2002-04
Phase Phase 3
Bristol-Myers Squibb

1,025 total trials

Why NCT00028067 stopped before completion

NCT00028067 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).

The record links to 0 conditions, and to 2 interventions - of which Atazanavir is the first listed.

NCT00028067 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00028067 about?

NCT00028067 is a clinical study titled "A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor". The purpose of this study is to compare the atazanavir and nelfinavir (NFV) treatments in their ability to reduce viral load.

What is the current status of trial NCT00028067?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2001-08. Estimated completion is 2002-04.

What interventions are being tested in trial NCT00028067?

The interventions under investigation include: Atazanavir (DRUG), Nelfinavir mesylate (DRUG).

Who is sponsoring clinical trial NCT00028067?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00028067's enrollment target sits among peer trials

500 744th of 2000 higher than 1,226 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00028067, the US trial registry maintained by the National Library of Medicine. NCT00028067 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.